From Yahoo Finance: 2025-04-15 13:45:00

The US pharmaceutical industry is seeing a unique trend with Chinese corporations involved in Big Pharma acquisitions. Chinese firms are gaining attention for their development skills, producing potent compounds at lower costs. This trend is expected to continue, impacting the industry. Some experts believe it may benefit while others fear it could harm American startups.

Pacira BioSciences, Inc. (NASDAQ:PCRX) is a specialty pharmaceutical company focusing on non-opioid pain management solutions. It reported record revenue of $701 million in 2024, driven by strong sales of products like EXPAREL. The company projects revenue growth between $725 million and $765 million for 2025, supported by increasing demand for non-opioid solutions amid opioid addiction risks.

Investor confidence in Pacira BioSciences, Inc. (NASDAQ:PCRX) is high due to its innovative pain therapies and commitment to non-opioid treatments. The company received FDA designations and secured reimbursement codes for its products, enhancing accessibility. With a strong product lineup and strategic focus, Pacira is positioned for continued success in pain management.

Ranked 7th on the list of best pharma stocks for long-term growth, Pacira BioSciences, Inc. (PCRX) faces competition from AI stocks for delivering higher returns in a shorter time frame. An AI stock has shown significant gains in 2025, outperforming popular AI stocks. For investors seeking a promising AI stock trading at a low multiple of earnings, exploring the report on the cheapest AI stock is recommended.



Read more at Yahoo Finance: Is Pacira BioSciences, Inc. (PCRX) the Best Pharma Stock to Buy for Long Term Growth?